dr. ramalingam on flaura findings in egfr-mutant nsclc
Published 6 years ago • 543 plays • Length 2:34Download video MP4
Download video MP3
Similar videos
-
2:09
dr. ramalingam on flaura trial results in egfr-mutant nsclc
-
1:08
dr. ramalingam on the os results of the flaura trial in egfr-mutant nsclc
-
2:22
dr. ramalingam on plasma egfr mutations as a predictor of response in nsclc
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
5:06
front-line osimertinib significantly lengthens overall survival in egfr-mutation positive nsclc
-
6:43
esmo 2018: dr. ramalingam shares insight on lung cancer studies
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
2:47
dr ramalingam on updates in lung cancer following the 2024 asco annual meeting
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
1:04
dr. fidler on relay trial results in egfr nsclc
-
5:14
new standard for treating stage 4 egfr nsclc
-
1:11
dr. gitlitz on egfr exon 20 insertion mutations in lung cancer
-
1:43
dr. ramalingam discusses the results of the phase iii revel study in nsclc
-
2:19
dr. wakelee on detection of egfr t790m mutation in nsclc